newsfilter
← Latest News
Business Wire·

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding